Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer

Journal of Endocrinological Investigation

Volumn 30, Issue 9, 2007, Pages 734-738

  Fiore, E ^a   Giustarini, E ^a   Mammoli, C ^a   Fragomeni, F ^a   Campani, D ^a   Muller, I ^a   Pinchera, A ^a   Giani, C ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anti thyroperoxidase antibodies; Autoimmune thyroiditis; Breast cancer; Thyroid autoimmunity

Indexed keywords

ESTROGEN RECEPTOR; THYROID ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; AUTOIMMUNITY; BREAST CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HASHIMOTO DISEASE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MASTECTOMY; POSTOPERATIVE PERIOD; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; THYROID DISEASE;

EID: 36949037985     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350810     Document Type: Article

References (19)

1. Giani C, Fierabracci P, Bonacci R, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab 1996, 81: 990-4.
2. Turken O, Narln Y, Demlrbas S, et al. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003, 5: R110-3.
3. Jiskra J, Limanova Z, Barkmanova J, Smutek D, Friedmannova Z. Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Physiol Res 2004, 53: 693-702.
4. Giustarini E, Pinchera A, Fierabracci P, et al. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol 2006, 154: 645-9.
5. Smyth PP, Shering SG, Kilbane MT, et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab 1998, 83: 2711-6.
6. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124: 966-78.
7. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 1975, 36: 1-85.
8. Clayton F, Hopkins CL. Pathologic correlates of prognosis in lymph node-positive breast carcinomas. Cancer 1993, 71: 1780-90.
9. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11: 155-68.
10. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17: 1474-81.
11. Giani C, Campani D, De Negri F, et al. Relationship between progesterone receptor, axillary node status and productive fibrosis in ductal infiltrating carcinoma of the breast. Appl Pathos 1989, 7: 225-32.
12. Marcocci C, Vitti P, Cetani F, Catalano F, Concetti R, Pinchera A. Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism. J Clin Endocrinol Metab 1991, 72: 209-13.
13. Molino A, Micciolo R, Turazza M, et al. Prognostic significance of estrogen receptors in 405 primary breast cancers: a comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 1997, 45: 241-9.
14. Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005, 15: 1253-9.
15. Tazebay UH, Wapnir IL, Levy O, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 2000, 6: 871-8.
16. Ruf J, Toubert ME, Czarnocka B, Durand-Gorde JM, Ferrand M, Carayon P. Relationship between immunological structure and biochemical properties of human thyroid peroxidase. Endocrinology 1989, 125: 1211-8.
17. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol 2003, 15: 725-30.
18. Spiotto MT, Yu P, Rowley DA, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002, 17: 737-47.
19. Kurts C, Miller JF, Subramaniam RM, Carbone FR, Heath WR. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J Exp Med 1998, 20, 188: 409-14.